<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445650</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-SLS-006</org_study_id>
    <nct_id>NCT03445650</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects With Sjögren-Larsson Syndrome (SLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the
      Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson
      Syndrome (SLS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Index Ichthyosis Severity (VIIS) Scaling severity score as assessed by the investigator.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Severity of scaling based on the VIIS score system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(VIIS) Erythema severity score.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Severity of erythema based on the VIIS score system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Maximum Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile.</measure>
    <time_frame>Efficacy assessment period (Week 1 through Week 24)</time_frame>
    <description>Transepidermal water loss.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Sjogren-Larsson Syndrome</condition>
  <arm_group>
    <arm_group_label>ADX-102 1% Topical Dermal Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of ADX-102 Topical Dermal Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 1% Topical Dermal Cream</intervention_name>
    <description>ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.</description>
    <arm_group_label>ADX-102 1% Topical Dermal Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of ADX-102 Topical Dermal Cream</intervention_name>
    <description>Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.</description>
    <arm_group_label>Vehicle of ADX-102 Topical Dermal Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is aged 3 years or older

          -  Subject has a genetically-confirmed diagnosis of SLS.

          -  Subject has active ichthyosis that is Grade 2 or higher on the VIIS scaling severity
             score.

          -  Females of child-bearing potential: Negative pregnancy test at Screening and Baseline
             Visits.

        Exclusion Criteria:

          -  Subject has evidence of a serious active infection.

          -  Systemic or topical retinoids or other topical medications, not including emollients,
             within the past 30 days Baseline Visit 1.

          -  Subject has received an investigational systemic or topically administered drug within
             the past 30 days prior to Baseline Visit 1.

          -  Subject is currently receiving immunosuppressive therapy, including intermittent or
             low-dose systemic corticosteroids.

          -  Subject has a known allergic reaction to any ingredients of study drug formulation.

          -  Subject has any clinically significant laboratory test abnormalities or a history of
             any other condition that, in the opinion of the Investigator, could compromise the
             subject's ability to comply with the protocol or that could compromise the subject's
             safety or the interpretation of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carolyn Soo, Pharm. D.</last_name>
    <phone>781-761-4904</phone>
    <email>csoo@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keith A. Choate, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William B. Rizzo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADX-102, Sjögren-Larsson Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Sjogren-Larsson Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

